Introduction
============

Rate control in atrial fibrillation (AF) patients who are refractory to or unable to take β-blockers or non-hydropyridine calcium channel blockers (CCBs) remains a significant concern. Although there is increase awareness about the potential pro-arrhythmic properties and toxicity of digoxin \[[@b1-krcp-37-130]\], this medication has been widely prescribed for decades and is recommended for rate control in AF, regardless of the patient's renal function or presence of structural heart disease \[[@b2-krcp-37-130]--[@b4-krcp-37-130]\]. Non-randomized analyses of data from a large AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) trial \[[@b5-krcp-37-130],[@b6-krcp-37-130]\] and other AF-related trials have shown a higher mortality associated with chronic digoxin treatment. Real-world data from large AF cohorts from the veterans administration \[[@b7-krcp-37-130]\] and health maintenance organizations \[[@b8-krcp-37-130]\] have also confirmed these findings. Contemporary literature suggests that chronic digoxin treatment is independently associated with a greater risk of cardiac and cerebrovascular mortality, which includes hospitalization \[[@b8-krcp-37-130],[@b9-krcp-37-130]\] and stroke in patients with AF \[[@b10-krcp-37-130]\]. In addition, this mortality risk seems to increase in digoxin-treated AF patients with pre-existing ischemic heart disease (IHD) \[[@b7-krcp-37-130],[@b11-krcp-37-130]\]. However, in the MAGIC (Medical Research Council Adjuvant Gastric Infusional Chemotherap) trial, digoxin treatment was not associated with a significant increase in cardiac mortality over the course of a one-month follow-up \[[@b12-krcp-37-130]\]. Because there is limited long-term data on the major determinants for digoxin-associated mortality in AF patients, we performed a retrospective analysis of a large cohort of AF patients and clarified the major clinical determinants of cardiac and cerebrovascular mortality in AF patients chronically treated with digoxin.

Methods
=======

From a total AF cohort of 1,480 patients, we retrospectively analyzed 402 consecutive digoxin-treated AF patients who were treated at the tertiary referral center of Eulji University Hospital, Daejeon, South Korea from March 2004 to August 2015. We use electronic medical records from the departments of cardiology, nephrology and neurology to obtain demographic, outpatient and in-patient medication data and intermittent serum digoxin concentrations (SDCs). Patients who were 18 years of age or older with electrocardiographically confirmed AF were included in the study. We considered the date of the patient's first admission or first visit to an outpatient clinic with a diagnosis of AF as the index digoxin prescription as the date of entrance into the study. Patients who were excluded from the study included those with transient AF, those who were likely to have perioperative AF (defined as having cardiopulmonary surgery), and those with hypothyroidism or hyperthyroidism within three months before AF treatment.

Ethics approval
---------------

The protocol was approved by the Institutional Review Board (IRB) of Eulji University Hospital (IRB number: 2018-03-118). The study protocol was in accordance with the ethical standards of the IRB of Eulji University Hospital and with the Declaration of Helsinki.

Definition of parameters
------------------------

We estimated the glomerular filtration rate (eGFR, mL/min/1.73 m^2^) using the Modification of Diet in Renal Disease (MDRD) equation and stratified chronic kidney disease (CKD) into five stages \[[@b13-krcp-37-130],[@b14-krcp-37-130]\]. IHD was defined as obstructive coronary artery disease with an increase in supply/demand mismatch precipitated by physical or emotional stress or concurrent illness in the documented computer tomography or coronary angiogram \[[@b15-krcp-37-130]\]. Heart failure was defined as a clinical syndrome that results from decreased systolic function with a documented decreased ejection fraction \[[@b16-krcp-37-130]\]. We collected data on prescriptions filled for digoxin, β-blockers, non-dihydropyridine CCBs, rhythm control drugs (flecainide, propafenone and amiodarone), diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, statins, aspirin, clopidogrel, and anticoagulants, as well as data for major adverse cardiac and cerebrovascular events (MACCEs) during the study follow-up period. Fatal MACCEs, the primary outcome, were defined as death from heart failure, fatal myocardial infarction, fatal stroke and sudden cardiac death during the follow-up period.

Statistical analysis
--------------------

We compared demographic data including underlying disease history, laboratory data, electrocardiogram, and medication history according to the occurrence of MACCEs during the study period. Continuous variables are expressed as means with standard deviations, and categorical variables are expressed as percentages. The independent sample *t* test and Pearson's chi-square test were used to compare normally distributed continuous variables and dichotomous variables, respectively. Cox regression hazard models were used to determine independent predictors for the occurrence of MACCEs. Multivariable analysis was adjusted for age, sex, diabetes, CHA~2~DS~2~-VASc, eGFR, and IHD. Patients were categorized into four groups according to pre-existing IHD and cut-off eGFR values of 60 mL/min/1.73 m^2^ in order to characterize the association between each group and MACCEs. A Kaplan-Meier Curve was plotted for the free-from MACCEs. Analyses were performed using MedCalc software (version 17.0; Ostend, Belgium). *P* values less than 0.05 were considered to be statistically significant.

Results
=======

Baseline characteristics
------------------------

In our study, 402 (27.2%) consecutive AF patients who were treated with digoxin at the time of prescription index and who had a median a follow-up of 19.0 months (interquartile range, 2.6--44.8 months) were enrolled from the divisions of nephrology, cardiology and neurology. The overall incidence of MACCEs was 12.1% for an average three-year follow-up. The MACCEs consisted of death from heart failure (46.1%), fatal stroke (26.9%), fatal myocardial infarction (15.3%) and sudden cardiac death from fatal ventricular arrhythmia (5.7%). [Table 1](#t1-krcp-37-130){ref-type="table"} lists the baseline characteristics of patients with and without MACCEs in this study. The group with MACCEs had a significantly higher prevalence of diabetes (36.5% vs. 22.3%), pre-existing IHD (57.7% vs. 31.7%), lower eGFR (60.0 ± 35.3 mL/min/1.73 m^2^ vs. 78.3 ± 35.0 mL/min/1.73 m^2^), and higher SDC (1.21 ± 0.88 ng/dL vs. 0.93 ± 0.81 ng/dL) when compared to those without MACCEs ([Table 2](#t2-krcp-37-130){ref-type="table"}).

Receiver operating characteristic (ROC) analysis showed that pre-existing renal dysfunction (cut-off: eGFR ≤ 60 mL/min/1.73 m^2^, CKD III--V) significantly predicted the occurrence of MACCEs with a sensitivity of 59% and a specificity of 66% (*P* = 0.001). We also stratified the AF group into both eGFR ≤ 60 mL/min/1.73 m^2^ (CKD III--V) and eGFR \> 60 mL/min/1.73 m^2^ (CKD I--II) subgroups according to CKD staging by a nephrologist \[[@b17-krcp-37-130],[@b18-krcp-37-130]\]. The AF group with renal dysfunction (eGFR ≤ 60 mL/min/1.73 m^2^, CKD III--V) also had a larger proportion of males, diabetes and a higher CHA~2~DS~2~-Vasc than the group with-out renal dysfunction (CKD I--II) ([Supplementary Table 1--3](#s1-krcp-37-130){ref-type="supplementary-material"}). Electrocardiogram data showed that AF patients with MACCEs had more frequent junctional bradycardia in the emergency room or intensive care unit than those without MACCEs ([Table 1](#t1-krcp-37-130){ref-type="table"}). The overall incidence of MACCEs was higher in patients with pre-existing IHD and renal dysfunction (eGFR ≤ 60 mL/min/1.73 m^2^) than in the AF group without pre-existing IHD and renal dysfunction.

Factors associated with MACCEs
------------------------------

In the Cox proportional hazards regression models, univariate analysis showed that CHA~2~DS~2~-VASc had a hazard ratio (HR) of 1.33 and a 95% confidence interval (95% CI) of 1.04--1.69 (*P* = 0.020). An eGFR ≤ 60 mL/min/1.73 m^2^ had a HR of 1.57 and a 95% CI of 1.27--3.47 (*P* = 0.001), and pre-existing IHD had a HR of 1.46 and a 95% CI of 1.21--3.27 (*P* = 0.001). However, multivariate analysis showed that pre-existing IHD and an eGFR ≤ 60 mL/min/1.73 m^2^ were significantly associated with MAC-CEs. We then grouped subjects into four categories: 1) pre-existing IHD(−) and eGFR \> 60 mL/min/1.73 m^2^; 2) pre-existing IHD(+) and eGFR \> 60 mL/min/1.73 m^2^; 3) pre-existing IHD(−) and eGFR ≤ 60 mL/min/1.73 m^2^; and 4) pre-existing IHD(+) and eGFR ≤ 60 mL/min/1.73 m^2^ ([Table 3](#t3-krcp-37-130){ref-type="table"}). The Kaplan-Meier curve showed that concurrent pre-existing IHD with an eGFR ≤ 60 mL/min/1.73 m^2^ was significantly associated with a lower MACCE-free survival during the 10-year follow-up ([Fig. 1](#f1-krcp-37-130){ref-type="fig"}). In multivariable analysis, concurrent pre-existing IHD with an eGFR ≤ 60 mL/min/1.73 m^2^ was significantly associated with a higher risk of MACCEs (HR, 3.35; 95% CI, 1.64--6.87; *P* \< 0.001) ([Table 3](#t3-krcp-37-130){ref-type="table"}).

Discussion
==========

In our study, data from AF patients receiving chronic digoxin treatment were collected, and the overall incidence of MACCEs was found to be 12.1% during the follow-up period. AF patients with fatal MACCEs had a significantly larger proportion of pre-existing IHD and renal dysfunction than those without fatal MACCEs. More specifically, concurrent renal dysfunction (cut-off: eGFR ≤ 60 mL/min/1.73 m^2^; CKD III--V) with pre-existing IHD was a major determinant of fatal MACCEs.

Present guidelines recommend digoxin as a rate control option in patients with AF, regardless of renal dysfunction or IHD \[[@b4-krcp-37-130]\]. It has been used in AF patients who were unsuitable for or who had poor compliance with β-blockers and non-dihydropyridine CCBs. The digoxin maintenance dose (0.125--0.25 mg daily) and its adjustment are recommended for patients with renal dysfunction, as CKD can reduce the drug's excretion \[[@b19-krcp-37-130],[@b20-krcp-37-130]\]. The monitoring of SDC is warranted in renal dysfunction patients with chronic digoxin treatment.

Recently, digoxin was shown to be significantly associated with an increased mortality risk in patients with AF \[[@b8-krcp-37-130],[@b9-krcp-37-130],[@b21-krcp-37-130]\], and previous results raised the question of what is the determinant for digoxin-related mortality in AF patients with chronic digoxin treatment. An AFFIRM secondary analysis showed that digoxin treatments were associated with all-cause and cardiac mortality \[[@b5-krcp-37-130]\]. AF patients treated with digoxin for six years had a higher proportion of pre-existing IHD than those not treated with digoxin, and the results showed an all-cause mortality with a HR of 1.41 and a 95% CI from 1.19 to 1.67. The study also showed cardiovascular mortality with a HR of 1.35 and a 95% CI from 1.06 to 1.71 and an arrhythmic mortality with a HR of 1.61 and a 95% CI from 1.12 to 2.30. In our study, digoxin-treated AF patients with MAC-CEs had a higher proportion of diabetes, pre-existing IHD and renal dysfunction than those without MACCEs, as shown in [Table 1](#t1-krcp-37-130){ref-type="table"}. In the multivariate Cox regression analysis, our study also showed that pre-existing IHD (HR, 1.21; 95% CI, 1.17--2.78; *P* = 0.011) and an eGFR ≤ 60 mL/min/1.73 m^2^ (HR, 1.27; 95% CI, 1.14--2.78; *P* = 0.016) were significantly associated with an increased risk of fatal MACCEs ([Table 3](#t3-krcp-37-130){ref-type="table"}).

The Digitalis Investigation Group trial showed that digoxin reduced hospitalization but not fatal MACCEs when compared with a placebo \[[@b22-krcp-37-130]\]. However, this *post-hoc* analysis was limited by its exclusion of AF patients at baseline \[[@b23-krcp-37-130]\] and by the lack of data on digoxin doses or the SDC, which were also not collected in the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) \[[@b24-krcp-37-130]\]. In our study, we collected and analyzed the digoxin maintenance dose and SDC in digoxin-treated AF patients. In addition, the digoxin maintenance dose (0.17 ± 0.15 mg vs. 0.15 ± 0.05 mg) was similarly prescribed between the AF patients with and without MACCEs. However, the SDC in the AF patients with MACCEs was higher than in those without MACCEs (1.21 ± 0.88 ng/dL vs. 0.93 ± 0.81 ng/dL, *P* = 0.023), which suggests that digoxin toxicity is significantly associated with the occurrence of fatal MACCEs in digoxin-treated AF patients. Our study also showed the association between the prescribed digoxin maintenance dose and digoxin-related fatal MACCEs in clinical practice.

In the *post-hoc* analysis from the ROCKET AF \[[@b24-krcp-37-130]\], digoxin treatment was used frequently in baseline AF (68%, male; average CHAD~2~ 3), and it was significantly associated with an increased risk of all-cause mortality (HR, 1.17; 95% CI, 1.04--1.32; *P* = 0.0093), vascular death (HR, 1.19; 95% CI, 1.03--1.39; *P* = 0.0201), and sudden death (HR, 1.36; 95% CI, 1.08--1.70; *P* = 0.0076). For rate control in AF patients being treated with other medications such as β-blockers (64%) and CCBs (25%), the findings of this study suggest that digoxin should not be a first-line therapy because it influenced the incidence of the MACCEs during the follow-up. In our study, β-blockers (30.8%) and non-dihydropyridine CCBs (15.4%) were less frequently used compared with a previous study. The effect of digoxin as monotherapy could minimize the effect of β-blockers and CCBs, which influence the incidence of MACCEs.

In the TREAT-AF study \[[@b7-krcp-37-130]\], the proportion of those receiving digoxin treatment was 98.5% for males, 93.1% for those with a CHAD~2~ score of 0 to 3, and 4.8% for those with pre-existing IHD and an average eGFR of 67 mL/min/1.73 m^2^. There was evidence of increased risk in patients with a pre-existing IHD (HR 1.49, 95% CI 1.34--1.67, and *P* = 0.002 in the full cohort; HR 1.45, 95% CI 1.26--1.66, and *P* = 0.077 in the propensity-matched cohort). In addition, with multivariate adjustment and propensity matching, digoxin was significantly associated with an increased risk of death among all strata of GFR, except in dialysis patients. However, there was still no evidence of effect modification in all strata of kidney function. In our study, we stratified the AF group into both eGFR ≤60 mL/min/1.73 m^2^ (CKD III--V) and eGFR \> 60 mL/min/1.73 m^2^ by ROC analysis in accordance with CKD management guidelines \[[@b17-krcp-37-130],[@b18-krcp-37-130]\]. In multi-variable Cox regression analysis, pre-existing IHD(−) and eGFR \> 60 mL/min/1.73 m^2^ was used as a categorical reference, and pre-existing IHD(+) and an eGFR ≤ 60 mL/min/1.73 m^2^ had a HR of 3.35 with a 95% CI of 1.64--6.87 (*P* \< 0.001). In the Kaplan-Meier analysis, pre-existing IHD(+) and an eGFR ≤ 60 mL/min/1.73 m^2^ was significantly associated with the occurrence of MACCEs ([Fig. 1](#f1-krcp-37-130){ref-type="fig"}). We suggest that concurrent pre-existing IHD with an eGFR ≤ 60 mL/min/1.73 m^2^ (CKD III--V) was a major determinant of digoxin-related MACCEs during the long-term follow-up period.

The MAGIC trial \[[@b12-krcp-37-130]\] consisted of 57.4% male patients with a CHA~2~DS~2~-VASc score of 3, combined β-blocker treatment (40.7% vs. 40.9%) and amiodarone treatment (31.9% vs. 9.9%). Their results were limited by not presenting the maintenance digoxin dose, SDC and renal function status between the digoxin and non-digoxin groups. Digoxin use during acute IHD was not associated with a significant increase in mortality after correcting for clinical characteristics and comorbidities during a short, one-month follow-up.

Until now, the impact of chronic digoxin use in AF patients with pre-existing IHD and renal dysfunction has not been studied. Therefore, our results are noteworthy because we analyze the association between CKD III--V with pre-existing IHD and the occurrence of MACCEs for AF patients taking a chronic digoxin maintenance dose over a long-term follow-up period.

Digoxin increases intracellular calcium concentrations, and the net increase in intracellular calcium activates further calcium release from the sarcoplasmic reticulum, which is responsible for increasing the effect of positive inotropic agents. The negative chronotropic effect of digoxin is largely attributed to increased vagal tone. The optimal SDC is ≤ 0.9 ng/dL with a narrow therapeutic range. A higher SDC could result in dissociated neuro-hormonal effects, a prolonged action potential, myocardial oxygen consumption and arrhythmogenicity, which could be associated with increased mortality \[[@b23-krcp-37-130]\]. Digoxin is also renally excreted, and doses should be adjusted according to renal function \[[@b18-krcp-37-130],[@b25-krcp-37-130]\]. Digoxin toxicity leads to both the frequent occurrence of junctional bradycardia and life-threatening ventricular arrhythmias and may increase cardiac and cerebrovascular ischemic events \[[@b11-krcp-37-130]\]. Frequent junctional bradycardia in AF may also allow for the development of a cardiogenic thromboembolic source in cerebrovascular events.

Our results suggest that close observation is needed in AF patients with concurrent pre-existing IHD and CKD III--V who are chronically treated with digoxin in order to prevent the occurrence of MACCEs.

Our study has several limitations. First, this study is a retrospective observational analysis in which pre-existing IHD or renal dysfunction was not randomly assigned to AF patients with chronic digoxin treatment. Despite the fact that we had consistent results, the study had a very small population and is likely subject to selection bias with single-center data. Second, we did not take into consideration that frail or elderly patients have poor drug adherence and that OAC therapy might not be the optimal treatment. Third, the data for digoxin use, decreased eGFR, and elevated SDC were derived from hospital admission records for a MACCE, which might be associated with worse outcomes. Fourth, although digoxin is widely used, it is not an essential treatment for AF. Therefore, our results cannot be generalized to the treatment of AF

In conclusion, our data suggest that chronic digoxin treatment in AF patients with concurrent pre-existing IHD and CKD III--V is significantly associated with a greater risk of fatal MACCEs and that these patients should be closely monitored. Large, prospective, multi-center, randomized controlled trials are needed to clarify these results.
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###### 

Baseline characteristics of patients without and with MACCE

  Characteristic            All patients (n = 402)   Without MACCE (n = 350)   With MACCE (n = 52)   *P* value
  ------------------------- ------------------------ ------------------------- --------------------- -----------
  Age (yr)                  68.6 ± 11.2              68.7 ± 11.2               68.4 ± 11.0           0.832
  Sex, male                 162 (40.3)               136 (38.9)                26 (50.0)             0.126
  Hypertension              265 (65.9)               78 (22.3)                 19 (36.5)             0.475
  Diabetes                  97 (24.1)                78 (22.3)                 19 (36.5)             0.025
  Pre-existing IHD          141 (35.1)               111 (31.7)                30 (57.7)             \< 0.001
  Heart failure             79 (19.7)                67 (19.1)                 12 (23.1)             0.505
  Stroke or TIA             97 (24.1)                84 (24.0)                 13 (25.0)             0.872
  eGFR (mL/min/1.73 m^2^)   75.9 ± 35.5              78.3 ± 35.0               60.0 ± 35.3           \< 0.001
   CKD stage I              128 (31.8)               116 (33.1)                12 (23.1)             
   CKD stage II             123 (30.6)               113 (32.3)                10 (19.2)             
   CKD stage III            113 (28.1)               96 (27.4)                 17 (32.7)             
   CKD stage IV             21 (5.2)                 16 (4.6)                  5 (9.6)               
   CKD stage V              17 (4.2)                 9 (2.6)                   8 (15.4)              
  CHA~2~DS~2~-VASc          3.7 ± 1.5                3.6 ± 1.5                 3.9 ± 1.4             0.060
  PAF                       19 (4.7)                 17 (4.9)                  2 (3.8)               0.730
  Heart rate (beats/min)    157 ± 70                 153 ± 77                  160 ± 63              0.839
  QRS duration (ms)         97 ± 32                  97 ± 34                   97 ± 31               0.922
  QTc interval (ms)         450 ± 37                 449 ± 38                  458 ± 35              0.114
  JB at ER or ICU           72 (17.9)                57 (16.3)                 15 (28.8)             0.027
  Ejection fraction (%)     51 ± 15                  52 ± 15                   51 ± 16               0.745
  ACE inhibitor or ARB      152 (37.8)               126 (36.0)                26 (50.0)             0.126
  β-blocker                 124 (30.8)               111 (31.7)                13 (25.0)             0.328
  Non-hydropyridine CCB     62 (15.4)                53 (15.1)                 9 (17.3)              0.632
  Anti-platelet agent       211 (52.4)               177 (50.6)                34 (65.4)             0.051
  Anti-coagulation agent    213 (53.0)               191 (54.6)                22 (42.3)             0.098
  Statin                    77 (19.2)                68 (19.4)                 9 (17.3)              0.717
  Digoxin dose (mg)         153 ± 77                 0.17 ± 0.16               0.15 ± 0.05           0.324
  Anti-arrhythmics, Ic      8 (2.0)                  7 (2.0)                   1 (1.9)               0.389
  Amiodarone                13 (3.2)                 12 (3.4)                  1 (1.9)               0.567

Data are presented as mean ± standard deviation or number (%).

ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CKD, chronic kidney disease; eGFR, estimated eglomerular filtration rate; ER, emergency room; ICU, intensive care unit; IHD, ischemic heart disease; JB, junctional bradycardia; MACCE, major adverse cardiac and cerebrovascular events; PAF, paroxysmal atrial fibrillation; TIA, transient ischemic attack.

###### 

Baseline laboratory characteristics of patients without and with MACCE

  Characteristic            Without MACCE   With MACCE    *P* value
  ------------------------- --------------- ------------- -----------
  Hemoglobin (g/dL)         12.9 ± 1.8      12.3 ± 3.0    0.771
  Albumin (g/dL)            3.7 ± 0.3       3.7 ± 0.2     0.864
  Urea nitrogen (mg/dL)     24.5 ± 14.8     30.9 ± 20.8   0.619
  Creatinine (mg/dL)        1.13 ± 0.98     2.21 ± 2.74   \< 0.001
  AST (IU/L)                107 ± 137       69 ± 41       0.331
  ALT (IU/L)                83 ± 134        46 ± 30       0.336
  ALP (IU/L)                114 ± 111       113 ± 74      0.395
  Total bilirubin (mg/dL)   1.0 ± 1.2       1.9 ± 3.6     0.047
  Na (mEq/L)                133 ± 5         133 ± 5       0.989
  K (mEq/L)                 4.0 ± 0.5       4.0 ± 0.7     0.557
  CRP (mg/dL)               1.9 ± 7.5       0.7 ± 10.4    0.612
  SDC (ng/mL)               0.93 ± 0.81     1.21 ± 0.88   0.023

Data are presented as mean ± standard deviation.

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; MACCE, major adverse cardiac and cerebrovascular events; SDC, serum digoxin concentration.

###### 

Cox regression analysis for predictors of MACCE

  Variable                Univariate   Multivariate                                          
  ----------------------- ------------ -------------- ------- ------ ----------------------- ----------
  Age                     1.01         0.98--1.03     0.310                                  
  Sex, male               1.74         1.00--3.00     0.046                                  
  Hypertension            1.22         0.07--2.14     0.470                                  
  Diabetes                1.65         0.93--2.90     0.087                                  
  Heart failure           1.19         0.62--2.28     0.580                                  
  Previous stroke         1.19         0.63--2.23     0.581                                  
  SDC (ng/dL)             1.37         0.93--2.02     0.106                                  
  CHA~2~DS~2~-VASc        1.33         1.04--1.69     0.020                                  
  eGFR ≤ 60               1.57         1.27--3.47     0.001   1.27   1.14--2.78              0.016
  IHD                     1.46         1.21--3.27     0.001   1.21   1.17--2.78              0.011
  IHD(−) and eGFR \> 60                                              Categorical reference   
  IHD(+) and eGFR \> 60                                       1.08   0.43--2.69              0.856
  IHD(−) and eGFR ≤ 60                                        1.07   0.41--2.80              0.881
  IHD(+) and eGFR ≤ 60                                        3.35   1.64--6.87              \< 0.001

CI, confidence interval; eGFR, estimated glomerular filtration rate (mL/min/1.73 m^2^); HR, hazard ratio, IHD, ischemic heart disease; MACCE, major adverse cardiac and cerebrovascular events; SDC, serum digoxin concentration.
